Gliclada® (30 mg) ʻO Gliclazide > He hoʻomaʻemaʻe a me ke pale aku

30 mg hoʻolahalaha ʻai papa

Aia ma ka papa papa

mea waiwai - gliclazide 30 mg

nā mea hoʻowalewale: hocohilohi (4000 **), hoclohi (100 **)

calcium carbonate, lactose monohydrate, colloidal silicon dioxide, magnesium stearate

** Ka waiwai o ka papala i koho ʻia no kahi 2% (m / v) i hoʻohāmi ʻia i ka wai o ka hypromellose

ʻO nā papa oval, mai ka keʻokeʻo a kokoke i ke keʻokeʻo, liʻiliʻi ka biconvex

ʻĀpana Pharmacotherapeutic

Me ke kumu o ka mālama ʻana i ka maʻi maʻi. ʻO nā haʻahaʻa hoʻoliʻi haʻahaʻa no ka hoʻokō waha. Nā hua palapala o nā sulfonylureas. ʻO ka Gliclazide

ATX code A10VB09

Ka hana lāʻau lapaʻau

Lapaʻau lāʻau

Hoʻomoe a me ka hoʻolele

Ma hope o ka lawe ʻana i ka lāʻau lapaʻau i loko, ua piha piha ka gliclazide mai ka gastrointestinal tract. Māhuahua ka holomua o ka gliclazide i ka plasma i ka holo mua o nā hola 6 ma hope o ka hoʻokele ʻana a hiki i ka pākaʻi e hoʻomau ana mai ka 6th a 12 mau hola. He haʻahaʻa loa ka ʻano o ka wae ʻana. ʻAʻole ʻai i ka ʻai ʻana i ke kiʻekiʻe o ka inu ʻana. ʻO ka laha hoʻoili ma kahi o 30 lita. ʻO ka pilina o ka protein plasma e pili ana i ka 95%. ʻO kahi awelika o kēlā me kēia lā o ka lāʻau Gliclada® e hōʻoia i ka mālama ʻana i kahi paʻa o ka glyclazide i loko o ke koko koko no nā mea he 24 mau hola.

Hoʻopili ʻia ka Gliclazide i loko o ka nui o ka puuwai. ʻAʻole i loaʻa i nā metabolites ka hopena i ka hana lāʻau lapaʻau. ʻO ka pilina ma waena o ke ʻano i lawe ʻia a hiki i 120 mg a me ke koo o ka lāʻau i ka plasma, he linear hilinaʻi nui i ka manawa.

ʻO ka hapa hapalua (T1 / 2) o gliclazide he 12-20 hola. Hoʻokuʻu ʻia ia ma nā kumuʻai ma ke ʻano o ka metabolites, emi mai ma kahi o 1% e hoʻopiʻi ʻia i ka urine i loli ʻole.

ʻO ka pharmacokinetics i nā hihia lapaʻau kūikawā

I ka poʻeʻelemakule, ʻaʻole i ʻike ʻia nā loli nui i ka maʻi lapaʻau i loko o nā lāʻau pharmacokinetic.

Lapaʻau lāʻau

ʻO Gliclada® kahi lāʻau lapaʻau hypoglycemic waha mai ka pūʻulu o nā derivatives o ka sulfonylurea o ka lua o ka hanauna, ka mea e ʻokoʻa i nā lāʻau like ʻole e ka neʻe ʻana mai kahi hā heterocyclic N-piha me kahi hāmeʻa endocyclic.

Hoʻohaʻahaʻa ka Glyclada® i ke kahe koko me ka hoʻowalewale ʻana i ka ʻōlelo huna e nā nūpepa ʻo Langerhans me nā pūpū R. Ma hope o ʻelua mau makahiki o ka mālama ʻana, e noho mau ana ka nui o ka insulin o ka postprandial a me nā mea huna o C-peptides. Ma ke ʻano 2 diabetes mellitus, hoʻōla hou ka lāʻau lapaʻau i ka piʻi koke o ka mea huna o ka insulin i ka pane ʻana i ka hoʻokomo o glucose a hoʻonui i ka lua o ka ʻikepili o ka insulin. Hoʻonui ʻia ka hoʻonui nui o ka huna ʻana i ka insulin i ka pane ʻana i ka hoʻoulu ʻana ma muli o ka ʻai kai a me ka hoʻokele glucose.

Hoʻopili i nā mea pili i ka metabolism, hiki iā Glyclada® ke hopena ma ka microcirculation. ʻO ka lāʻau lapaʻau e hōʻemi i ka hopena o ka trombosis moku koko liʻiliʻi, e hoʻopiʻi ai i nā hana ʻelua i hiki ke komo i ka hoʻomohala ʻana i ka hoʻopiʻi i ka maʻi diabetes mellitus: hoʻokaʻa ʻāpana o ka pākuʻi o platelet a me nā ʻihi a me ka hoʻokaʻawale ʻana o nā mea hoʻāla o ka platelet activation (beta-thromboglobulin, thromboxane B2), a me ka hoʻihoʻi ʻana o fibrinolytic hana viva endothelial a me ka hana he nui o ka kiko o ka plasminogen kiko hana.

ʻLoe a me ke kākele

Ke koho ʻia nei ka lāʻau lapaʻau wale nō no nā mea maʻi.

A ʻōlelo ʻia e lawe i ka papa (me) ʻole o ka huki ʻana i ka wā o ka ʻaina kakahiaka. Inā poina ʻoe i ka lā aʻe ma ka lā aʻe, ʻaʻole hiki iā ʻoe ke hoʻonui i ka nui.

ʻO ka lā maʻamau o Glyclad® mai 30 a 120 mg (1 a 4 mau papa). Koho ʻia ka nui o ka lāʻau ma muli o ka pane kūʻokoʻa o ka mea maʻi.

ʻO ka paipai hoʻomaka ʻia he 30 mg i kēlā me kēia lā. Me ka kaohi o ka glucose mau maikaʻi, hiki ke hoʻohana ʻia kēia ʻano ma ke ʻano o ka mālama mālama ʻana.

Me ka lawa ʻole o ka pae o ka glucose, hiki ke hoʻonui ʻia ka nui o ka lā i ka lā 60, 90 a 120 mg. ʻO ka palena ma waena o kēlā me kēia piʻi e piʻi ka liʻiliʻi ma kahi o 1 malama, koe wale nō nā maʻi i hōʻemi i ka pae o ka glucose ma hope o 2 mau pule o ka hoʻokele. I ia mau hihia, hiki ke hoʻonui ʻia ka momona i mau hebedoma 2 ma hope o ka hoʻomaka ʻana o ka maʻi. ʻO ka dosis momona kiʻekiʻe e 120 mg i kēlā me kēia lā.

Ke hoʻololi ʻana mai ka 80 mg Glyclazide Papa i nā Glyclad Hoʻolaha Hoʻolaha®

Ma ka hopena o ka hoʻokele pono o ka hoʻoliʻi o ka glucose i ke koko o ka mea maʻi me nā papa he 80 glycoslide, hiki ke hoʻololi ʻia me Glyclada® i ka pae o ka 1 papa o glycoslide 80 mg = 1 papa o Glyclada®.

Ke hoʻololi ʻana mai kekahi lāʻau lapaʻau hypoglycemic hou iā Glyclad®

Ma ka hoʻololi hou, pono e noʻonoʻo ʻia ka nui a me ka hapalua o ke ola ma mua. ʻAʻole koi ʻia kahi manawa hoʻololi. ʻO ka ʻae i ka lāʻau Glyclada® e hoʻomaka me 30 mg, ukali ʻia e ka hoʻoponopono e pili ana i ka hopena o ka metabolic.

Ke hoʻololi nei i nā lāʻau lapaʻau'ē aʻe o ka pūʻulu sulfonylurea me kahi hapa hapa o ka lōʻihi, i mea e pale ai i ka hopena hoʻohui o nā lāʻau ʻelua, hiki i kahi hana manu ʻole no kekahi mau lā ke koi.

I kēlā me kēia pilikia, pono ka hoʻololi ʻana i nā papa Glyclad® me ke ʻano neʻe mua ʻana o 30 mg, ukali ʻia e ka nui phased ma ka maʻi i ka mea hoʻokalakupua.

Hoʻohana me ka hui pū me nā lāʻau lapaʻau antidiabetic

Hiki ke kuhikuhi ʻia ka Gliclada® e hui pū me nā biguanides, alpha-glucosidase inhibitors a i ʻole insulin. Hoʻomaka ʻia nā ʻākana o ka insulin i lalo o ka mākaʻikaʻi koʻikoʻi o kahi kauka.

Nā maʻi maʻi (ma lalo o 65 mau makahiki)

Ua kuhikuhi ʻia ka lāʻau lapaʻau i loko o ka heiau like i nā mea maʻi ma lalo o ka makahiki 65.

I ka poʻe maʻi me ka hana hāmeʻa ʻole ʻole a me ke kaulike, ua hāʻawi ʻia ka lāʻau lapaʻau i nā kaha maʻamau.

ʻO nā mea maʻi me ka piʻi nui o ka hypoglycemia: me ka pōʻino, me ka maʻi nui a palaka paha i ka hopena endocrine (hypopituitarism, hypothyroidism, nele o ka adrenocorticotropic hormone), ma hope o ka lōʻihi o / a me ka lāʻau lapaʻau corticosteroid koʻikoʻi, nā maʻi cardiovascular koʻikoʻi, a ʻoi aku ka maʻi ʻana e hoʻomaka ʻia me ka liʻiliʻi i kēlā me kēia lā o 30 mg.

Nā hopena hopena

ʻO ka hypoglycemia (ma ke ʻano he hanana ʻole o ka ʻai a i ʻole kaʻai ʻana i ka ʻai): ka ʻeha, ka pōloli nui, ka walaʻau, ka luaʻi, ka luhi, ka hiamoe ʻana, hoʻomākeʻe, hōʻāwīwī, ka pīhoihoi, ka hopohopo ʻana i ka nānā ʻana, e hoʻolohi ana i ka hopena, ke kaumaha, ka poʻokela, ka nānā ʻana a me ka haʻi. , ka aphasia, paresis, haʻalulu, ka hoʻohaʻahaʻa i ka naʻau, dizziness, bradycardia, nā hoʻopaʻi, ka nalowale o ka pale ʻana i ka puhaka, ka pohō, ka nalo hāhā, ka nalowale o ka noʻonoʻo, ka lauwili, e alakaʻi nei i ka coma a me ka make. Hiki i nā hōʻailona Adrenergic: pili kaomi, nā hopohopo, tachycardia, hoʻonui ke koko, ke ʻeha o ka naʻau, arrhythmia

ʻeha ka ʻōpū, hōʻeha, ka luaʻi, ke ʻehaʻeha, constipation (hiki ke hōʻemi ʻia e ka lawe ʻana i ka lāʻau i ka wā kakahiaka)

ka ulu ʻana i ka pae o ka hoʻōla o ka hepatic (ALT, AST, phosphatase alkal), hepatitis (jarang), hyponatremia

ka ʻāʻī o ka ʻili, kaʻeha, ka urticaria, angioedema, erythema, rashes maculopapular, nā hopena bullous (e like me ka Stevens-Johnson syndrome, nā toxic epidermal necrolysis)

anemia, leukopenia, thrombocytopenia, granulocytopenia, pancytopenia (huli ʻia ma hope o ka hōʻemi ʻana i ka lāʻau)

ka hiʻona o ka holomua o ke kino, no ka hoʻomaka ʻana o ka mālama ʻana, ma muli o nā loli o ke kaila o ke koko

Nā Hoʻohui

kaulana hypersensitivity i gliclazide a i ʻole o kekahi o nā mea kōkua o ka lāʻau lapaʻau, a me nā lāʻau ʻē aʻe o ka pūʻulu sulfonylurea a i nā sulfonamides

maʻi diabetes type 1

maʻi ketoacidosis maʻi, precomatosis a me ka piko maʻi maʻi

pilikia hōʻeha a i ʻole kaʻohi ʻana

hapai a lactation

Hoʻopili i nā lāʻau lapaʻau

Hoʻohui ʻia ka hoʻohana pū ʻana o ka gliclazide a me ka miconazole e pili ana i ka hopena o ka pilikia o hypoglycemia, a hiki i ka hypoglycemic coma.

ʻAʻole i ʻōlelo ʻia ʻo Glyclazide e hoʻohana i ka manawa like me ka phenylbutazone a me ka waiʻona ma muli o ka hoʻonui nui o ka hypoglycemia. I ka wā o ka mālama ʻana me ka lāʻau lapaʻau, pono ia e pale i ka inu ʻana i ka wai ʻona a lawe ʻana i nā lāʻau lapaʻau e pili ana i ka waiʻona.

I ka pili me ka pilikia o ke kūkulu ʻana i ka hypoglycemia, pono e mālama ʻia ka mālama ʻana i ka wā e kuhikuhi ai i ka gliclazide a me nā lāʻau antidiabetic o nā hui ʻē aʻe (insulins, acarbose, biguanides), beta-blockers, fluconazole, angiotensin-hoʻohuli i ka hoʻohui o nā enzyme (captopril, enalapril), a me H2 receptor antagonists, (IMAO), sulfonamides a me nā mea hoʻohana anti-inflammatory non-steroidal.

ʻO ka hoʻohana pinepine ʻana o gliclazide a me danazol, ʻaʻole i hoʻolako ʻia ma muli o ka loaʻa o ka piʻi o ka nui o ka glucose o ke koko. Inā pono, ʻo ke koho ʻana o ia ʻano hui e pono e kiaʻi pono i ka pae o ka glucose i loko o ke koko a me ka maʻi wai, a ma kekahi mau hihia, e hoʻoponopono i ka nui o ka gliclazide i ka wā e mālama ai me ka danazol a ma hope o ka pane.

I ka ʻike o ka hopena o ka hoʻomohala ʻana i ka hyperglycemia, pono e hoʻomaʻamaʻa ʻia ka wā e hoʻohui ʻana i ka gliclazide me ka chlorpromazine (ma kahi kikoʻī o> 100 mg i kēlā me kēia lā, ʻo ia ka mea e hoʻoneʻe ai i ka emi ʻana o ka huna ʻana i ka insulin). No ka lōʻihi o ke kūlaʻi o ka chlorpromazine, pono e koi ʻia kahi hoʻoponopono o ka gliclazide.

ʻO Glucocorticosteroids (no ka ʻōnaehana kūloko a me ke kūloko: intraarticular, sub- a i ʻole subcutaneous, rectal) a me tetracosactides, i ka wā e hui pū me ka glycoslazide, hoʻonui i nā pae glucose koko a, ma muli o ka emi ʻana o ka hoʻohaʻahaʻa kalalau, hiki ke hōʻeha i ka ketosis. I ka wā o ka mālama ʻana a ma hope o ke kūpaʻa glucocorticoid, e koi ai i kahi hoʻoponopono o gliclazide.

Pono e mālama ʻia i ka mālama ʻana i ka hoʻohana pū ʻana o ka gliclazide me ka ritodrine, salbutamol a me tertbutaline (intravenously) ma muli o ke kaʻe o ka hoʻomohala ʻana i ka hyperglycemia. Inā pono, e hele i ka lāʻau lapaʻau insulin.

Me ka hoʻohana pū ʻana o ka gliclazide me nā anticoagulants (warfarin, etc.), e nānā ʻia ka nui o ka hopena anticoagulant.

Nā ʻōlelo kikoʻī

Pono ka lāʻau lapaʻau e wehewehe wale ʻia me ka hana maʻamau o ka meaʻai e ka mea maʻi (me ka ʻaina kakahiaka).

Hōʻalo ka hopena o ka hypoglycemia me kahi meaʻai haʻahaʻa-haʻahaʻa, ma hope o ka manawa lōʻihi a i ʻole ka nui o ka hoʻoikaika kino, inu ʻana i ka wai inu, a i ʻole ʻia me ka hoʻohana pū ʻana o kekahi mau lāʻau hypoglycemic.

I ka ʻike ʻana i ka hoʻonui nui o ka hypoglycemia, ua ʻōlelo ʻia e lawe pinepine ʻoe i nā mea kālaiʻai i ka maʻamau (inā i pau ka nui o ka ʻai, inā ua ʻai ʻia ka ʻai, a inā i ʻole ka liʻiliʻi o ka ʻai.

Hiki i ka hypoglycemia e ulu ma hope o ka hoʻohana ʻana i nā derivatives o sulfonylurea. Hiki i kekahi mau hihia ke koʻikoʻi a lōʻihi i ka lōʻihi. E koi ʻia no ka hila, a e koi ʻia paha ka glucose i nā lā he nui.

No ka hōʻemi i ka pilikia o ka hoʻomohala ʻana i nā hopena hypoglycemic, e pono ai ke aʻo ʻana i ka mea maʻi.

Hoʻokomo i nā mea i hoʻonui i ka hiki i ka hypoglycemia:

Hemo

ʻO ka laupili o Renal a me ka pohō: Hiki i ke pharmacokinetic a me nā huahana pharmacodynamic o gliclazide ke loli i nā mea maʻi me ka maʻi hepatic a i ʻole ke kaumaha ʻole. ʻO nā maʻi Hypoglycemic e hele mai ana i ia mau maʻi e hiki ke lōʻihi ka lōʻihi, a no laila e pono ke mālama ʻia.

Pono e ʻike ʻia ka mea maʻi e pili ana i ka pono o kaʻai ʻana, ka pono o ka hoʻoikaika kino a me ka mālama pinepine ʻana i nā pae glucose koko. Pono ka poʻe maʻi a me kā lākou mau ʻohana e wehewehe i ka pōʻino o ka hypoglycemia, ke kamaʻilio e pili ana i kona mau hōʻailona, nā ala lapaʻau a me nā mea i manaʻo ʻia i ka hoʻolālā ʻana o kēia hoʻopiʻi ʻana.

Ka ʻike koko glucose ka maikaʻi

Hiki ke hopena i ka hopena o ke kaohi ʻana o ka glucose i loko o ke koko o ka mea maʻi e loaʻa ana i ka lāʻau antidiabetic e pili ana i nā mea kumu: maʻi, ka ʻehaʻeha o ke kino, ʻeha, a i ʻole hōʻoki ʻana. I kekahi mau hihia, pono paha ke kuhikuhi i ka insulin.

Ma ka hopena o ka hypoglycemic o kekahi lāʻau lapaʻau antidiabetic waha, me ka gliclazide, i nā mea maʻi he nui i ka wā ma muli o ka ulu ʻana o ka maʻi maʻi a i ʻole ka hōʻemi ʻana i ka pane i ka lāʻau lapaʻau (nele i ka hopena o ka hopena o ka terapi). ʻO ka hopena e pili ana i ka nele o ka lua o ka hopena o ka lapaʻau hiki ke hana wale nō ma hope o ka hoʻoponopono ʻia ʻana o ka maʻi kūpono a inā makemake ka mea maʻi i kahi meaʻai.

I ka loiloi ʻana i ka kaohi o ke koko o ke koko, e hōʻike ʻia ana e helu ʻia ka pae o ka hemoglobin glycated (a i ʻole ka ʻai ʻana o ka wela o ka plasma o ke koko venous).

Ke kuhikuhi nei i nā lāʻau lapaʻau sulfonylurea i nā maʻi me ka glucose-6-phosphate dehydrogenase hiki ke alakaʻi i ka hemolytic anemia. Pono e mālama ʻia i ka wā e koho ai i ka gliclazide i nā mea maʻi me ka nele o ka glucose-6-phosphate dehydrogenase a e noʻonoʻo i ka hana hou ʻana me kahi lāʻau lapaʻau like ʻole.

ʻO kaʻikepili kūikawā ma nā mea kūʻai aku

ʻO ka Gliclada® ka lactose. ʻO nā maʻi me nā maʻi i hoʻoili ʻole ʻia ka galactose intolerance, Lapp lactase deficiency a glucose-galactose malabsorption ʻaʻole pono e lawe i kēia lāʻau lapaʻau.

Nā hiʻohiʻona o ka hopena o ka lāʻau lapaʻau ma ka hiki ke hoʻokau i nā kaʻa a i ʻole nā mea e hoʻopilikia ai paha

Hoʻohana pono ʻia ka mālama ʻana i ka wā e lawe ai i nā kaʻa a i ʻole nā ʻoihana ʻē aʻe, ʻoiai ma ka hoʻomaka ʻana o ke ʻano.

Ke keu

Nā Hoʻomaka hōʻemi ʻia i ka hypoglycemia koʻikoʻi.

Lāʻau: nā hōʻailona o ka hypoglycemia maʻalahi me ka nalowale ʻole o ka ʻike a hōʻailona ʻole paha i ka maʻi neurological, e hoʻopau ana i ka hoʻokomo o nā karoli, hoʻoponopono ʻia a hoʻoponopono ʻia a i ʻole kekahi hoʻololi i ka meaʻai. Pono ke nānā ʻana i nā kauka olakino e hoʻomau a hiki i ke kauka ke hoʻomau a paʻa i ka maʻi.

ʻO nā hopena hōʻeha o ka hypoglycemia, i hele pū me ka coma, nā hoʻopaʻi a i ʻole nā pilikia neurological ʻē aʻe, e koi aku i ka mālama wikiwiki a me ka hoʻouka maʻi. Inā hele mai ka poʻomaka hypoglycemic coma a i hopohopo paha, ʻo glucoseagon a me 50 ml o ka hopena o ka glucose kūpono (20-30% intravenously) e koke koke ʻia, a hoʻomau i ka infusion o 10% o ka hopena o ka glucose i ka hopena e hōʻoia ai e pili ana i ka hoʻoliʻiliʻi ʻana o ke koko ma mua o 1 g / l . ^ E Ha yM. Pono ka mea maʻi ma lalo o ka mālama koʻikoʻi lāʻau. ʻAʻole maikaʻi kēlā Hemodialysis.

ʻĀpana Pharmacological

ʻO nā mea kūmole hypoglycemic oral, sulfonamides, nā urea derivatives. Kiwi ATX A10V B09.

ʻO Glyclazide kahi lāʻau lapaʻau hypoglycemic oral, kahi derphative sulfonylurea, kahiʻokoʻa mai nā lāʻau lapaʻau'ē aʻe ma ke alo o kahi heterocyclic hāmeʻa i loaʻa ka nitrogen a he mau mea paʻa endocyclic.

Hoʻopau ke Glyclazide i nā pae kaila glucose ma muli o ka hoʻoulu ʻia o ka huna huna e nā ʻona ʻona e nā ʻona sela o nā mokupuni o ka pancreatic o Langerhans. ʻO ka hoʻonuiʻana i ka pae o ka insulin postprandial a me nā mea huna o ka C-peptide e mau nei a ma hope o ka 2 mau makahiki o ka hoʻohana ʻana i ka lāʻau. Loaʻa iā Gliclazide i nā mea hemovascular.

Ka hopena i ka huna ʻana i ka insulin.

I ka poʻe maʻi me ka maʻi type II, ke hoʻihoʻi nei ka gliclazide i ka mua o ka neʻe o ka huna ʻana o ka insulin i ka pane ʻana i ka hoʻokomo o glucose a hoʻonui i ka lua o ka ʻōlelo huna o ka insulin. Hoʻonui nui ʻia ka hoʻonui ʻana i ka ʻenehana insulin ma muli o ka ʻai kai a me ka ukana ʻai.

Hoʻololi ʻo Glyclazide i ka microthrombosis ma muli o nā mea hana e hiki ai ke hoʻopili i ka hoʻomohala ʻana o nā hoʻopiʻi o ka maʻi mellitus:

hoʻokaʻawale i kekahi o nā platelet aggregation a me ka hoʻopulapula, e hōʻemi i ka nui o nā māka hoʻohuihui platelet (β-thromboglobulin, thromboxane B 2)
pili i ka hana fibrinolytic o votone endothelium (hoʻonui i ka hana TRA).

ʻO ka pahuhopu mua nā mea nui o nā hanana macrovascular (make cardiovascular, non-lethal myocardial infarction, non-lethal stroke) a me ka microvascular (nā hihia hou a i ʻole e ulu ana i nā nephropathy, retinopathy) i nā hanana.

Ua hoʻokomo ʻia nā maʻi 11,140 i nā hoʻokolohua hoʻokolohua. I loko o 6 mau hebedoma o ka manawa i hoʻolauna ʻia, hoʻomau nā poʻe maʻi i kā lākou maʻa mau i ka hana hoʻokaʻa gula. A laila, e like me ke kumu maʻalahi, ua hāʻawi ʻia i nā mea maʻi ka hoʻoponopono glycemic control regimen (n = 5569) a i ka regimen me ke kaʻi ʻana o ka glycoslide, nā kāpena i hoʻokuʻu ʻia, e pili ana i ke hoʻolālā no ka pale glycemia control (n = 5571). Hoʻokumu ʻia ka hoʻolālā no ka pili glycemic control i ke koho ʻana i ka gliclazide, nā papa me kahi kenekulia i hoʻololi ʻia, mai ka hoʻomaka ʻana o ka hoʻōla ʻana, a i ʻole ma ke kau ʻana o gliclazide, nā papa me ke kala e hoʻololi ʻia, ma kahi o ka maʻamau maʻamau (ʻo ia ka hopena i loaʻa i ka mea maʻi i ka manawa hoʻopili.) me ka hoʻohui o nā lāʻau lapaʻau e hoʻohaʻahaʻa ʻē aʻe, inā pono, e like me metformin, acarbose, thiazolidinediones a i ʻole insulin. Ka nānā kiaʻi maikaʻi ʻia nā mea maʻi.

Ua mau ka nānā ʻana i ka 4.8 mau makahiki. ʻO ka hopena o ka mālama ʻana me ka gliclazide, i hoʻokuʻu ʻia i nā papa hoʻoneʻe, ʻo ia ke kumu o ka hoʻolālā no ka kontrol glycemic intensive (awelika pae kiʻekiʻe o HbAlc - 6,5%) hoʻohālikelike me ka mana o ka glycemia maʻamau (pae kiʻekiʻe pae hoʻokele o HbAlc - 7.3%), he nui ka hōʻemi nui. 10% mau pilikia pili i ka hoʻopiʻi nui o nā macro- a me nā hoʻopiʻi microvascular ((HR) 0.90, 95% Cl 0.82, 0.98 p = 0.013, 18.1% o nā mea maʻi mai ka hui pūohi kūlohelohe i hoʻohālikelike ʻia me 20% o nā maʻi mai ka hui ʻohi maʻamau). ʻO nā pono o ka hoʻolālā no ka hoʻomohalaʻana i ka glycemic control me ka wae ʻana o gliclazide, hoʻoponopono ʻia i hoʻokuʻu ʻia i loko o ke kumu o ka hopena ma muli o:

ka hoʻohaʻahaʻa nui ʻana i ka hopena pili i nā hanana mikoleka nui ma o 14% (HR 0.86, 95% Cl 0.77, 0.97, p = 0.014, 9.4% kūlike 10,9%),
ka hopena nui o ka hopena pili i nā hihia hou a i ʻole ka holo ʻana o ka nephropathy e 21% (HR 0.79, 95% Cl 0.66 - 0.93, p = 0.006, 4.1% kūlike 5.2%).
kahi hōʻemi nui o 8% ma ka pili pili i ka microalbuminuria i hana i ka manawa mua (HR 0.92, 95% Cl 0.85 - 0.99, p = 0.030, 34.9% kū'ē i ka 37.9%),
ka hoʻemi nui ʻana ma ka hopena o ka hopena o nā hanana i ka hanana 11% (HR 0.89, 95% Cl 0.83, 0.96, p = 0.001, 26.5% kūʻē kūloi.

I ka hopena o ke aʻo ʻana, ua 65% a me 81.1% o nā mea maʻi i ka pūʻulu kikowaena o ke kuahiwi (kū'ē i ka 28.8% a me 50.2% o ka pūʻulu mana hoʻoponopono) i hoʻokō ʻo HbAlc ≤ 6.5% a me ≤ 7%, kēlā me ia. ʻO 90% o nā mea maʻi ma ka pūʻulu kikowaena paipai i lawe gliclazide, mau papa me ka hoʻokuʻu ʻia (hoʻohaʻahaʻa ʻia i kēlā me kēia lā he 103 mg), 70% o lākou ua lawe i ka nui loa o kēlā me kēia lā o 120 mg. Ma ka hui o ka mana glycemic control e pili ana i ka gliclazide, i hoʻoponopono ʻia i nā papa, hoʻololi ʻia ke kino kino o ka mea maʻi.

ʻO nā mea kūpono o ka hoʻolālā no ka uluʻana o ka glycemic control e pili ana i ka gliclazide, i hoʻokuʻu ʻia i nā papa ʻaina, ʻaʻole i hilinaʻi ʻia i ke kahe koko.

Ke piʻi nei ke kiʻekiʻe o ka gliclazide i ke koko koko i ka manawa o 6:00 mua, e hōʻea ana i kahi pā e hiki ana i ʻeono a i ka ʻumikūmālua hola ma hope o ka lawelawe ʻana i ka lāʻau.

Hōʻalo ʻia nā hue wale nō.

Hoʻopili maikaʻi loa ʻia ʻo Glyclazide. ʻAʻole make ka ʻai i ka helu a me ka nui o ka kahe.

ʻO ka pilina o ka protein plasma e pili ana i ka 95%. ʻO ka pilina ma waena o ka hopena i lawe ʻia ma ka awelika a hiki i ka 120 mg a me ka mahele i lalo o ka manawa o ka pīpī ʻana-manawa ka lime. ʻO ka laha hoʻoili ma kahi o 30 lita.

Hoʻomili ʻia ka Gliclazide i loko o ka pulu a hoʻoulu ʻia i loko o ka mimi; ua emi mai ka 1% o ka hana ikaika a pau i ka urine i loli ʻole. ʻAʻohe huahana metabolites ikaika i loko o ka plasma.

ʻO ka hapalua hapalua o ka gliclazide he 12-20 hola.

I nā poʻe maʻi maʻi, ʻaʻohe mau loli nui i loko o ka lāʻau lapaʻau o ka lāʻau.

ʻO kahi iki hoʻokahi o ka lāʻau lapaʻau ʻo Glyclada, nā papa me kahi hoʻokuʻu i hoʻololi ʻia, mālama i ka paʻa o ka glycazide i loko o ka plasma no 24 mau hola.

ʻAno II mellitus mika:

hōʻemi a kāohi i ka glucose o ke koko ma ka hihia o ka hiki ke hoʻonoho i ka nui o ka glucose ma o kaʻai ʻana, i ka hoʻomaʻamaʻa ʻana a i ʻole ka momona kaumaha
ka pale ʻana o nā hoʻopiʻi ʻana o ka maʻi II mellitus maʻi II: hōʻemi i ka hoʻoneʻe ʻana o ka maʻi macro- a me nā hoʻopiʻi microvascular, me nā hihia hou a i ʻole ka weliweli nephropathy i nā maʻi me ka maʻi II mellitus type II.

Mea hana

Krka, dd ʻO Novo Mesto, Slovenia

Šmarješka 6, 8501 Novo Mesto, Slovenia

ʻO ka noho ʻana o kahi hui e ʻae ana i nā koi mai nā mea kūʻai aku ma ka maikaʻi o nā huahana (nā huahana) i ka Repubalika o Kazakhstan

Krka Kazakhstan LLP, Kazakhstan, 050059, Almaty, Al-Farabi Ave. 19, kūkulu hale 1 b,

Hoʻopili me nā lāʻau lapaʻau a me nā ʻano ʻē aʻe ʻē aʻe

Ke hoʻohana nei i nā lāʻau lapaʻau, ka hoʻokaʻawale ʻana o nā hopena e hiki ai i ka hyp- a i ka hyperglycemia, hoʻolaha ke Sidid i ka mea maʻi e pili ana i ka pono o ka mālama pono ʻana i ke kaʻe o ka glucose koko i ka wā o ka mālama ʻana. Hiki ke koi ʻia ka hoʻoponopono ʻana i ka lāʻau hypoglycemic i ka wā a ma hope o ka mālama ʻana me kēia mau lāʻau.

Hiki i nā lāʻau lapaʻau ke hoʻonui i ka ulu o ka hypoglycemia

Hoʻonui ka Miconazole (no ka hoʻohana systemic, oromucous gel) i ka hopena hypoglycemic me ka hiki ke hoʻomohala ʻia nā hōʻailona o ka hypoglycemia a i ʻole coma.

ʻAʻole i hāʻawi ʻia

Hoʻonui ka Phenylbutazone (no ka hoʻohana ʻana i nā ʻōnaehana) i ka hopena hypoglycemic o ka sulfonylurea (hoʻohuli i kāna pili me nā protein plasma a / a i ʻole ia e hōʻemi i kona hopena). Hoʻomaopopo ʻia e hoʻohana i kahi lāʻau hou anti-inflammatory a huki i ka nānā o ka mea maʻi i ka pono a me ka mea nui o ka kāohi ponoʻī. Inā pono, ke hoʻoponopono ʻia ka nui o ka lāʻau o Glyclad i ka manawa a ma hope o ke ʻano lāʻau lapaʻau anti-inflammatory.

Hoʻonui ka waiʻona i ka hopena hypoglycemic (ma ke kāohi ʻana i nā hoʻoneʻeneʻe uku), hiki iā ia ke alakaʻi i ka hoʻomaka ʻana o ka comog hypoglycemic. Pōʻalo iā ka hoʻohana ʻana i nā lāʻau lapaʻau e pili ana i ka waiʻona, a me ka hoʻohana ʻana i ka wai inu.

ʻO nā hui e koi ana i ka mālama

Ke hoʻoikaika nei i ka hopena hypoglycemic o ka lāʻau, a ma kekahi mau mea, ulu mai ka hypoglycemia ma muli o ka hoʻohana ʻokoʻa ʻana o nā lāʻau antidiabetic e like me nā lāʻau lapaʻau (insulin, acarbose, metformin, thiazolidinediones, dipeptidyl peptidase 4 inhibitors, glucose-1-phosphate receptor agonists), beta blockers, ACE inhibitors (captopril, enalapril), H 2 receptor antagonists, MAO inhibitors, sulfonamides, clarithromycin, and non-steroidal anti-inflammatory drugs.

ʻO nā lāʻau lapaʻau e hiki ai i ka piʻi o nā glucose koko

ʻAʻole i hāʻawi ʻia

Danazole: ʻO ka hopena maʻi diabetes o Danazol.

Inā ʻaʻole hiki ke pale ʻia ka hoʻohana ʻana o kēia ʻano hana, pono e hōʻike ʻia ka mea maʻi e pili ana i ka pono a me ka pono o ka mālama pono ʻana o ka glucose i ka urine a me ke koko. Pono paha e hoʻoponopono i ka hopena o nā mea antidiabetic i ka wā a ma hope o ka mālama ʻana me ka danazol.

ʻO nā hui e koi ana i ka mālama

ʻO Chlorpromazine (antipsychotic): ka hoʻohanaʻana i nā kaha kiʻekiʻe o chlorpromazine (> 100 mg i kēlā me kēia lā) e hoʻonui i ka pae o ka glucose i ke koko (ma muli o kahi kahe o ka huna ʻana i ka insulin).

Pono e hōʻike ʻia ka mea maʻi e pili ana i ka pono a me ka mea nui o ka mālama ʻana i nā pae glucose koko. Hiki paha iā ia ke hoʻoponopono i ka pāopiha o nā mea hoʻoikaika antidiabetic i ka wā a ma hope o ka mālama ʻana o nā antipsychotics.

ʻO Glucocorticoids (no ka hoʻohana ʻana i ka systemic a me ka topical: intraarticular, ka ʻili a me ka hoʻomākaukau i ka aho) a me ka tetracosactrin e hoʻonui i ka hoʻoliʻi koko me ka hoʻomohala nui ʻia o ka ketosis (ma muli o ka hōʻemi o ka hoʻokaʻawale ʻana o nā palaka ma ka glucocorticoids).

Pono e hōʻike ʻia ka mea maʻi e pili ana i ka pono a me ka mea nui o ka mālama ʻana i nā pae glucose koko, ʻoi aku hoʻi i ka hoʻomaka ʻana o ka mālama ʻana. Hiki paha iā ia ke hoʻoponopono i ka ʻai ʻana o nā ʻaina antidiabetic i ka wā ma hope o ka mālama ʻana i ka glucocorticoid.

ʻO Ritodrin, salbutamol, terbutaline (c) hoʻonui i ka pae o ka glucose i ke koko ma muli o nā agonist beta-2.

Pono e hōʻikeʻia e pili ana i ka pono e mālama i nā pae i ka glucose koko. Inā pono, e hoʻoneʻe i ka mea maʻi i ka insulin.

ʻO nā hui e kiaʻala no

ʻO ka maʻi me nā anticoagulants (e like me ka warfarin, a me nā mea) i hoʻomākaukau ʻia ai ka sulfonylurea e hiki ai ke hoʻoikaika i ka hopena anticoagulant me ka hoʻoulu ʻana. Hiki ke koi ʻia ka hoʻoponopono ʻo Anticoagulant.

Nā hiʻohiʻona noi

Hoʻomaopopo ʻia ka mālama ʻia ʻana i nā maʻi e hiki ai ke hahai i kahi ʻai piha a me ka maʻamau (me ka ʻaina kakahiaka). He mea nui ia e hoʻopau pinepine i nā pōkole ma muli o ka hoʻonui nui o ka hypoglycemia, e loaʻa ana i ka wā e huli ai ka meaʻai, i kahi haʻahaʻa ʻole kālā, a inā i haʻahaʻa ka meaʻai i nā mea hōʻalo. Hoʻopilikia ka pilikia o ka hypoglycemia me ka mālama haʻahaʻa-calorie i ka lōʻihi, ka lōʻihi a me ka hana kino olakino, me ka waiʻona a i ʻole ka hui pū ʻana o nā mea hana hypoglycemic.

Hiki i ka hypoglycemia ma muli o ka hana like o ka hoʻomākaukau ʻana o ka sulfonylurea a (ʻike i ka "Nā hopena ʻino") i kekahi mau mea i hikiʻole ke hoʻopili a lōʻihi. I kekahi manawa ke koi ʻia ka hoʻokipa ʻana a me ka hoʻohana ʻana i ka glucose i nā lā he nui.

Ka nānā iki ʻana i nā maʻi maʻi, ka hoʻohana ʻana o kekahi ʻano lāʻau i ka lāʻau a me ka paʻa pono ʻana i ka nui ma ka hoʻoponopono ʻana a me ka hoʻoponopono ʻia noi ʻana ke pono e hōʻemi i ka hopena o ka hypoglycemia.

Hoʻokomo i nā mea i hoʻonui i ka hiki i ka hypoglycemia:

hōʻole a (ʻole paha i nā poʻe maʻi maʻi) hiki ʻole i ka mea maʻi ke hana pū ʻana,
nā kīʻaha haʻahaʻa a kū ʻole paha i nā mea ʻai, nā mea kīʻaha, nā manawa hoʻokē ʻai a loli paha i ka meaʻai.
ka pale hewaʻana o ka kaulike ma waena o ka hana kino a me ka pae o ka intake o ka kalaka,
nā mālamalama maikaʻi ʻole
uhaiki pohihihi
he keu o ka Glyclad,
kekahi mau maʻi o ka ʻōnaehana endocrine: maʻi thyroid, hypopituitarism a me ka adrenal insufficiency,
ka hoʻohana like ʻana o kekahi mau lāʻau lapaʻau ʻē aʻe (e ʻike i ka mahele "Hoʻopili i nā lāʻau lapaʻau a me nā ʻano ʻē aʻe ʻē aʻe".

ʻO ka laupili o Renal a me ka pohō

Hiki i nā pharmacokinetics a me / a i ʻole nā lāʻau lapaʻau o ka gliclazide i loli i ka mea maʻi me ka maʻi hepatic a i ʻole ka hopena paʻakikī. Hiki ke hoʻonui ʻia nā manawa hōʻailona o ka hypoglycemia e loaʻa ana i kēlā mau maʻi i ka lawelawe ʻana i nā laʻi.

ʻO ka ʻike maʻi

ʻO ka mea maʻi a me nā ʻohana ʻānō e pono e ao ʻia e pili ana i ka pilikia o ka hypoglycemia, e wehewehe i kāna mau hōʻailona (e nānā i ka ʻāpana "Nā Haumahaʻōlelo ʻino"), ʻo ka mālama ʻana, a me nā mea e hoʻonui ai i ka hopena o kona ulu ʻana.

Pono ka poʻe maʻi e hoʻomaopopo i ka pono o kaʻai, ka hoʻomaʻamaʻa maʻamau, a me ka ʻike o ka nui o ka glucose koko.

ʻO ka hanaʻole o ka hoʻoponopono o ka glucose koko

Hiki i nā mea kumu ke hoʻopilikia i ka ka mālama ʻana i nā pae o ka glucose koko i loko o nā mea maʻi e lawe nei i nā lāʻau antidiabetic: maʻi, ʻeha, ʻeha, a me nā hōʻola paha. I kekahi mau hihia, pono ʻia ka insulin.

ʻO ka hopena hypoglycemic o kekahi lāʻau lapaʻau antidiabetic, me ka gliclazide, e emi ana i ka manawa i loko o nā mea maʻi he nui: hiki paha kēia ma muli o ka ulu ʻana o ka hōʻeha o ka maʻi maʻi a i ʻole ka hōʻemi o ka pane i ka hoʻomaʻamaʻa. Hōʻike ʻia kēia ʻano kuʻi keu lua ʻole, ka ʻokoʻa ʻana mai ka mea nui me ka maikaʻi ʻole ka hana ikaika i ka lāʻau me ka lālani laina mua. Pono e hoʻoponopono ʻia kahi hoʻoponopono kūpono a me ka papaʻai ma mua o ka hoʻopuka ʻana i ka mea maʻi i ka hui kaulua lua.

Kuhi ʻia e hoʻoholo i ke kiʻekiʻe o ka glycosylated hemoglobin (a i ʻole ka pae o ke kō i ka hookeai ma ka wai koko venous). Pono pono ka nānā ʻana i ke kahe koko.

ʻO ka mālamaʻana i nā mea maʻi me ka nele o ka glucose-6-phosphate dehydrogenase me ka hoʻomākaukau ʻana o ka sulfonylurea hiki ke alakaʻi i ka anemia hemolytic. No ka mea ʻo ka gliclazide pili i ka papa kemana o ka hoʻomākaukau ʻana o ka sulfonylurea, pono e mālama ʻia nā mea maʻi me ka maʻi glucose-6-phosphate dehydrogenase;

ʻO ka mālama mālama kūikawā e pili ana i kekahi ʻāpana

ʻO ka Gliclada ka lactose. ʻO nā mea maʻi me ka lolika lactose līhoʻī hemahema, ʻaʻole me ka galactosemia a i ʻole ka laikini glucose-galactose malabsorption e lawe i kēia lāʻau.

Hoʻohana i ka wā hāpai a lactation.

ʻAʻohe mea i ʻike me ka hoʻohana ʻana o gliclazide i ka wā hapai, ʻoiai aia kekahi mau hōʻike e pili ana i ka hoʻohana ʻana o nā mea ʻoniʻoni ʻē aʻe.

Pono e hoʻokokoke ʻia ka maʻi diabetes ma mua o ka wā hapai e hōʻemi i ka hopena o ka maʻi congenital e pili ana me ka nele o ka mālama ʻana i ka maʻi diabetes.

ʻAʻole kōkua ʻia ka hoʻohana ʻana i nā lāʻau antidiabetic waha, ʻo ka insulin ka lāʻau nui no ka mālama ʻana i ka maʻi maʻi i ka wā hāpai. Hoʻomaopopo ʻia e ka hoʻololi i ka mea maʻi i ka insulin i ka wā o kahi hapai i hoʻolālā ʻia a i ka wā e kū ʻia ai.

ʻAʻole ʻike nā ʻikepili ma ka komo ʻana o ka gliclazide a i ʻole nā metabolites i ka waiū umauma. Hāʻawi ʻia i ka hopena o ka ulu ʻana o ka hypoglycemia i kahi keiki, ua hoʻohana ʻia ka hoʻohana ʻana i ka lāʻau i loko o nā wahine e ʻānai ana.

ʻO ka hiki ke hoʻokaumaha i ka hopena o ka hopena i ka wā e holo a hana paha me nā hana ʻē aʻe.

ʻAʻole i ʻike ʻia ʻo Gliclada i ka hiki ke hoʻokele kaʻa a hana paha me nā mīkini. Akā, e makaʻala nā mea maʻi e pili ana i ka hoʻomaka ʻana o nā hōʻailona o ka hypoglycemia e akahele i ka wā e holo a hoʻohana ʻole i nā mīkini, pono i ka hoʻomaka ʻana o ka mālama ʻana.

ʻO nā hopena ʻino

E pili ana i ka ʻike me ka dericatives gliclazide a me ka hopena o ka sulfonylurea, ua hōʻike ʻia ka hopena hope loa.

ʻO kaʻaiʻai kūʻai, a me ka mea maʻamau, ʻo kahi pōkole i ka wā o ka maʻi me ka hoʻomākaukau ʻana o ka sulfonylurea, me ka Glyclad, hiki i ka hoʻomohala ʻana i ka maʻi hypoglycemia. Nā hōʻailona hōʻeha e hiki ai i ka hypoglycemia: hōʻeha, ka pōloli nui, ka hoʻomaha, ka luaʻi, ka luhi, ka hiamoe i ke kaumaha, ka hopohopo, nā huhū, ka pīhoihoi, ka hopohopo, a me ka hoʻoluhi i nā hopena, nā hopohopo, nāʻike a me ka waha e hoʻopuka, aphasia, huhū, paresis , hōʻeha, ka nalowale ʻana o ka pale ponoʻī, delirium, hōʻino, pāpila pāpū, bradycardia, ʻeha, hoʻoluhi ka ʻike, a me ka hoʻomohala ʻana o ka coma me kahi hopena make.

Eia kekahi, hōʻike ʻia nā hōʻailona o ka ʻōnaehana adrenergic: hoʻonui nui ʻana, ka ʻūhū ʻana i ka ʻili, ke hopohopo, tachycardia, hypertension arterial, palpitations puʻuwai, angina pectoris a me arrhythmia.

Kuhi pinepine nā ʻōhua ma hope o ka lawe ʻana i ka ʻai (sugar). Eia naʻe, ʻaʻohe hopena o ka mea momona maoli. Hōʻike ka ʻike me nā hoʻomākaukau he no ka olonylurea hiki i ka hypoglycemia ke hoʻokuʻi pinepine ʻia, ʻoiai inā i lawe pono nā hana kūpono.

Inā paʻakikī a paʻa paha nā hopena o ka hypoglycemia, ʻoiai ia e hoʻomalu ʻia e ka kōʻai gula, pono ka lawelawe hoʻokipa a me ka nānā ʻana i nā maʻi lapaʻau.

ʻO ka hapanui o nā hihia o ka hypoglycemia e nānā ʻia i nā mea maʻi me ka hoʻomohala ʻana i ka lāʻau insulin.

ʻO nā hopena ʻē aʻe

Mai ka ʻeha o ka gastrointestinal: ʻeha o ka ʻōpū, nausea, ka luaʻi, ka dyspepsia, nā ʻōpū a me ka constipation. Hiki ke hoʻopau ʻia a i ʻole ka hōʻemi ʻia kēia mau hōʻailona ma ka lawe ʻana i ka gliclazide i ka wā kakahiaka kakahiaka kakahiaka.

ʻO nā hopena hou aʻe no nā hopena kūpono ʻole.

Ma ka ʻāpana o ka ʻili a me ka kiko subcutaneous: rash, itching, urticaria, angioedema, redness, maculopapular rash, bullous reaction (e.g. Stevens-Johnson syndrome and toxic epidermal necrolysis).

Mai nā pūnaehana kaila a me ka lymphatic: nā loli i nā ʻāpana hematological, me ka anemia, leukopenia, thrombocytopenia, granulocytopenia. Kūpono kēia mau hanana a maalo pinepine i ka pau ʻana o ka lāʻau.

Ma ka ʻāpana o ka pūpū a me ka pāhau o ka hāpē: kahi hoʻonui i ka pae o ka hoʻonaninani o ka ate (AST, ALAT, phosphatase alkaline), hepatitis (mau hihia). I ka hihia o ka jaundice cholestatic, pono e hoʻokaʻawale ʻia ka hoʻohana ʻana i ka lāʻau.

Mai ka ʻaoʻao o ka waihona o ka ʻike: ka waʻa kaulike o ka ʻike pōkole, ma muli o nā loli o ka nui o ka glucose i loko o ke koko, e hele wale ana ka ʻike maka pōkole, ma ka hoʻomaka ʻana o ka mālama ʻana.

Nā hopena i loaʻa i nā huahana sulfonylurea:

E like me ka hoʻomākaukau ʻana o ka sulfonylurea, aia nā hihia o ka erythrocytopenia, agranulocytosis, hemolytic anemia, pancytopenia, allergic vasculitis, hyponatremia, hoʻohuihui i nā aʻalima puhilahi a me ka hana i nā aho hemahema (no ka laʻana, me ka cholestasis a me jaundice) a me ka hepatitis e nalowale ma hope o ka hoʻomālamalama ʻana a i ʻole nā hihia a pau i alakaʻi i ke ola hōʻeha ola.

ʻO nā waiwai Pharmacological

Hoʻopau ka Gliclazide i nā taumata glucose o ka plasma ma muli o ka hoʻouluʻana o ka huna huna e ka huna ʻona e nā cells a sela o nā mokupuni pancreatic o Langerhans. ʻO ka hoʻonuiʻana i ka pae o ka insulin postprandial a me nā mea huna o ka C-peptide e mau nei a ma hope o ka 2 mau makahiki o ka hoʻohana ʻana i ka lāʻau.

Loaʻa iā Gliclazide i nā mea hemovascular.

Ka hopena i ka huna ʻana i ka insulin.

Hoʻololi ʻo Gliclazide i ka microthrombosis e nā mea hana i hiki ke komo i ka hoʻomohala ʻana o nā hoʻopiʻi o ka maʻi mellitus:

hoʻokaʻawale i kekahi o nā platelet aggregation a me ka hoʻopulapula, e hōʻemi i ka nui o nā māka hoʻohuihui platelet (β-thromboglobulin, thromboxane B 2)
pili i ka hana fibrinolytic o votone endothelium (hoʻonui i ka hana TRA).

ʻO ka pale ʻana i nā hoʻopiʻi o ka maʻi II.

ʻO ADVANCE kahi hana hoʻokolohua multicenter pā honua me ka hoʻolālā ʻana o ka bi-factorial, ke kuhikuhi ʻana i ka ʻike ʻana i nā pōmaikaʻi o kahi hoʻolālā control glycemic (HbAlc ≤ 6.5%) e pili ana i nā papa pā glycoslide i hoʻololi ʻia (Gliclazide MR) i hoʻohālikelike ʻia i ka mana glycemic maʻamau a me nā pono o ka hoʻohaʻahaʻa i ke koko. ke kaomi nei me ka hoʻohui pū ʻana o ka perindopril / indapamide i hoʻohālikelike ʻia me ka placebo ma ke kaʻe o ka ʻenehana maʻamau o kēia manawa (hoʻohālikelike makapō ʻelua) e like me ka hopena ma ka nui nā micro- a me nā hanana microvascular i nā maʻi me nā maʻi II ʻano II.

ʻO ka noiʻi ʻana me 11 mau mea maʻi me ka diabetes mellitus type II (ʻo ia hoʻi: ʻo ka makahiki 66 mau makahiki, BMI (index body body) 28 kg / m 2, ka lōʻihi o ka maʻi maʻi 8 mau makahiki, ka pae HbAlc o 7.5% a me SBP / DBP (systolic kahe koko / diastolic blood pressure) 145/81 mmHg). I waena o kēia mau mea maʻi, ua loaʻa he 83% i ka maʻi hypertension, ma nā maʻi he 325 a i 10%, ua ʻike ʻia nā maʻi macro- a me nā micro-vascular ma ka mōʻaukala o kēia maʻi, kēlā, a ma 27%, ua ʻike ʻia ka microalbuminuria (MAU). Ua mālama ʻia ka hapa nui o ka poʻe maʻi ma mua o ka maʻi II, 90% - ma ka lawe ʻana i ka lāʻau lapaʻau (47% - monotherapy, 46% - ʻelua mau lāʻau a me ka 7% - triple therapy) a me 1% me ka insulin a ʻo ka 9% aia wale nō i ka meaʻai. I ka wā mua, ʻo sulfonylurea (72%) a me ka metformin (61%) ua kuhikuhi mua ʻia. ʻO nā hui hoʻohui i ka 75% o nā lāʻau lapaʻau e hoʻohaʻahaʻa i ke koko (BP), nā lāʻau hōʻemi lipid (35%, ka nui o nā statins - 28%), aspirin a me nā mea hana antiplatelet (47%). I loko o ka manawa 6 pule o ka lawelawe o ka hui ʻana o ka perindopril / indapamide a me ka hoʻohiolo ʻana i ke kō - a me ka hoʻohiolo, hoʻokaʻawale ʻia nā mea maʻi me ke kumu holoʻokoʻa (n = 5569), a i ka hoʻoponopono kaua glycazide e pili ana i ka hoʻolālā o ka hoʻomālamalama glycemia intensive (n = 5571). Kahi ʻia ka hoʻolālā no ka ʻike glycemic control ma ke kuhikuhi ʻana i ka Gliclazide MR mai ka hoʻomaka ʻana o ka mālama ʻana a i ʻole ke kuhikuhi ʻana i ka Gliclazide MR ma kahi o ka maʻi maʻamau (ʻo ke ʻano a ka mea maʻi i loaʻa ai i ka manawa e komo ai) me ka hoʻonui nui aʻe o ka hopena i ka loa a laila, inā pono, ka hoʻohui ʻia ʻana o nā lāʻau lapaʻau haʻahaʻa. metformin, acarbose, thiazolidinediones a i ole insulin. Ka nānā kiaʻi maikaʻi ʻia nā mea maʻi.

Ua mau ka nānā ʻana i ka 4.8 mau makahiki. ʻO ka hopena o ka lapaʻau ʻana ʻo Gliclazide MR, ʻo ia ka kumu o ka hoʻolālā no ka mālama glycemic intensive (ka nui o ka pae ʻo HbAlc i ka 6.5%) hoʻohālikelike i ka mana o ka glycemia maʻamau (ʻo ka pae ākea ʻo HbAlc pae ʻo 7.3%), kahi hōʻemi nui o 10% mau hoahānau ka hopena o ka hoʻopiʻi nui o nā macro- a me nā hoʻopiʻi microvascular ((HR) 0.90, 95% Cl 0.82, 0.98 p = 0.013, 18.1% o nā mea maʻi mai ka hui pūohi kūlohelohe i hoʻohālikelike ʻia i ka 20% o nā maʻi mai ka hui mana hoʻokolohua maʻamau. ʻO nā pono o ka hoʻolālā no ka hoʻomohalaʻana i ka glycemic control me ka wae ʻana o ka MR gliclazide e pili ana i ka therapy ma muli o:

ka hoʻemi nui ʻana o ka hopena o ka hopena o nā hanana mikoleka nui ma o 14% (HR 0.86, 95% Cl 0.77, 0.97, p = 0.014, 9.4% vs. 10,9%),
ka hōʻemi nui ʻana i ka hopena pili i nā hihia hou a i ʻole ka piʻi ʻana o ka nephropathy ma o 21% (HR 0.79, 95% Cl 0.66 - 0.93, p = 0.006, 4.1% vs. 5.2%),
ka hoʻēmi nui ʻana ma ka hopena pili i ka microalbuminuria, i hōʻea i ka manawa mua, ma 8% (HR 0.92, 95% Cl 0.85 - 0.99, p = 0.030, 34.9% kūlana 37.9%),
ka hoʻemi nui ʻana ma ka hopena o ka hopena o nā hanana i ka hanana 11% (HR 0.89, 95% Cl 0.83, 0.96, p = 0.001, 26.5% vs. 29.4%).

I ka hopena o ke aʻo ʻana, ua 65% a me 81.1% o nā mea maʻi i ka hui puʻukui mea paʻakikī (vs 28.8% a me 50.2% o ka pūʻulu mana hoʻoponopono) hoʻokō i ka pahuhopu HbAlc o ≤ 6.5% a me ≤ 7%, ma kēlā.

ʻO 90% o nā mea maʻi ma ka puʻupuʻu ikaika neʻe i lawe ma Gliclazide MR (ka awelika o kēlā me kēia lā he 103 mg), 70% o lākou ua lawe aku i ka nui loa o kēlā me kēia lā o 120 mg. I ka hui pūʻana o ka glycemic control e pili ana i ka Gliclazide MR, ua hoʻomau ʻia ka paona kino o ka mea maʻi.

Kahi pōmaikaʻi o ka Glycoslazide MR-based intly glycemic control did not depend on lower blood.

Ke piʻi nei ke kiʻekiʻe o ka gliclazide i loko o ke koko koko i ka manawa o 6:00 mua, e hōʻea ana i kahi ala e hoʻomau ana no nā hola 6-12 ma hope o ka hoʻomakeʻa ʻana o ka lāʻau lapaʻau. Hoʻopau piha ka Gliclazide i ka gastrointestinal tract. ʻAʻole make ka ʻai i ka helu a me ka nui o ka kahe.

ʻO ka pilina ma waena o ka inikua a hiki i ka 120 mg a me ka mahele i lalo o ka manawa o ka paʻa-manawa ka lime. ʻO ka pilina ʻana i ka protein plasma he 95%.

ʻO Gliclazide kahi i hoʻohālikelike nui ia i ka pūpū a hoʻopili i ka pā. ʻOi aku ka liʻiliʻi ma 1% o gliclazide e hoʻololi i ka loli. ʻAʻohe huahana metabolites ikaika i loko o ka plasma.

ʻO ka hapalua hapalua o ka gliclazide mai ke kino he 12-20 hola. ʻO ka laha hoʻoili ma kahi o 30 lita.

Ke hoʻohana nei i hoʻokahi ka lāʻau o ka lāʻau lapaʻau, mālama ʻia ka ʻike o gliclazide i ke koko koko no 24 mau hola.

I nā poʻe maʻi maʻi, ʻaʻole i loli nui nā ʻōmole pharmacokinetic.

He haʻahaʻa loa ka loli o intra-pilikino.

ʻAno II mellitus mika:

hōʻemi a kāohi i ka hoʻoliʻi o ke koko inā hiki ʻole ke hoʻokaʻawale i ke kiʻekiʻe o ka glucose ma o kaʻai ʻana, hoʻomaʻamaʻa ʻana a i ʻole ka momona kaumaha
ka pale ʻana o nā hoʻopiʻi ʻana o ka maʻi II mellitus maʻi II: hōʻemi i ka hoʻoneʻe ʻana o ka maʻi macro- a me nā hoʻopiʻi microvascular, me nā hihia hou a i ʻole ka weliweli nephropathy i nā maʻi me ka maʻi II mellitus type II.

KeikiHo

Hoʻohana i ka wā hāpai a lactation

ʻAʻole kōkua ʻia ka hoʻohana ʻana i nā lāʻau antidiabetic waha, ʻo ka insulin ka lāʻau nui no ka mālama ʻana i ka maʻi maʻi i ka wā hāpai. Hoʻomaopopo ʻia e ka mea maʻi e hoʻoneʻe i ka insulin i ka hopena o ka hapai i hoʻolālā ʻia a i ka wā e kū ʻia ai.

ʻAʻole ʻike nā ʻikepili ma ka komo ʻana o ka gliclazide a i ʻole nā metabolites i ka waiū umauma. Ma muli o ke ʻano o ka ulu ʻana o ka hypoglycemia i loko o kahi keiki, pono e hoʻohana ʻia ka hoʻohana ʻana i ka lāʻau no ka manawa o ka umauma.